Access the full text.
Sign up today, get DeepDyve free for 14 days.
A. Stewart, M. Dimopoulos, T. Masszi, I. Špička, A. Oriol, R. Hájek, L. Rosiñol, D. Siegel, R. Niesvizky, A. Jakubowiak, J. San-Miguel, H. Ludwig, S. Rajkumar, J. Buchanan, K. Cocks, X. Yang, B. Xing, N. Zojwalla, M. Tonda, P. Moreau, A. Palumbo (2015)Superior Health-Related Quality of Life with Carfilzomib, Lenalidomide, and Dexamethasone versus Lenalidomide and Dexamethasone in Patients With Relapsed Multiple Myeloma (MM): Results From the ASPIRE Trial
Clinical Lymphoma, Myeloma & Leukemia, 15
R. Niesvizky, T. Martin, W. Bensinger, M. Alsina, D. Siegel, L. Kunkel, A. Wong, Susan Lee, R. Orlowski, Michael Wang (2013)Phase Ib Dose-Escalation Study (PX-171-006) of Carfilzomib, Lenalidomide, and Low-Dose Dexamethasone in Relapsed or Progressive Multiple Myeloma
Clinical Cancer Research, 19
M. Dimopoulos, P. Richardson, P. Moreau, K. Anderson (2015)Current treatment landscape for relapsed and/or refractory multiple myeloma
Nature Reviews Clinical Oncology, 12
Aspire Investigators (2015)Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma.
The New England journal of medicine, 372 2
F. Parlati, Susan Lee, M. Aujay, E. Suzuki, K. Levitsky, J. Lorens, D. Micklem, P. Ruurs, C. Sylvain, Yan Lu, K. Shenk, M. Bennett (2009)Carfilzomib can induce tumor cell death through selective inhibition of the chymotrypsin-like activity of the proteasome.
Blood, 114 16
S. Demo, C. Kirk, M. Aujay, T. Buchholz, M. Dajee, M. Ho, Jing Jiang, Guy Laidig, E. Lewis, F. Parlati, K. Shenk, M. Smyth, Congcong Sun, M. Vallone, Tina Woo, C. Molineaux, M. Bennett (2007)Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome.
Cancer research, 67 13
M. Rael, Á. Benedict, J. Ishak, S. Cadarette, M. Campioni, S. Panjabi (2015)Indirect Comparisons to Assess the Relative Efficacy of Carfilzomib + Lenalidomide + Dexamethasone Versus Panobinostat + Bortezomib + Dexamethasone and Bortezomib + Dexamethasone: A Matching Adjusted Indirect Comparison
Bo Hu, Yu Chen, S. Usmani, Shi-qiao Ye, Wei Qiang, X. Papanikolaou, C. Heuck, S. Yaccoby, B. Williams, F. Rhee, B. Barlogie, J. Epstein, Y. Qiang (2013)Characterization of the Molecular Mechanism of the Bone-Anabolic Activity of Carfilzomib in Multiple Myeloma
PLoS ONE, 8
A. Badros, R. Vij, T. Martin, J. Zonder, L. Kunkel, Zhengping Wang, Susan Lee, A. Wong, R. Niesvizky (2013)Carfilzomib in multiple myeloma patients with renal impairment: pharmacokinetics and safety
A. Jakubowiak, D. Dytfeld, K. Griffith, D. Lebovic, D. Vesole, S. Jagannath, A. Al-Zoubi, Tara Anderson, Brian Nordgren, K. Detweiler-Short, K. Stockerl-Goldstein, Asra Ahmed, Terri Jobkar, D. Durecki, Kathryn McDonnell, M. Mietzel, D. Couriel, M. Kaminski, R. Vij (2012)A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma.
Blood, 120 9
Michael Wang, T. Martin, W. Bensinger, M. Alsina, D. Siegel, E. Kavalerchik, Mei Huang, R. Orlowski, R. Niesvizky (2013)Phase 2 dose-expansion study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma.
Blood, 122 18
J. Harousseau, M. Dreyling (2010)Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Annals of oncology : official journal of the European Society for Medical Oncology, 21 Suppl 5
(2015)Kyprolis (carfilzomib) 60 mg powder for solution for infusion: EU summary of product characteristics
D. Kuhn, Qing Chen, P. Voorhees, John Strader, K. Shenk, Congcong Sun, S. Demo, M. Bennett, F. Leeuwen, A. Chanan-Khan, R. Orlowski (2005)Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma.
Blood, 110 9
M. Dimopoulos, P. Moreau, A. Palumbo, D. Joshua, L. Pour, R. Hájek, T. Facon, H. Ludwig, A. Oriol, H. Goldschmidt, L. Rosiñol, J. Straub, A. Suvorov, C. Araujo, E. Rimashevskaya, T. Pika, G. Gaidano, K. Weisel, V. Goranova-Marinova, A. Schwarer, L. Minuk, T. Masszi, Ievgenii Karamanesht, M. Offidani, V. Hungria, A. Spencer, R. Orlowski, H. Gillenwater, N. Mohamed, S. Feng, W. Chng (2016)Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study.
The Lancet. Oncology, 17 1
M. Rael, Á. Benedict, J. Ishak, S. Cadarette, M. Campioni, S. Panjabi (2015)Indirect Comparison to Assess the Relative Efficacy of Carfilzomib + Lenalidomide + Dexamethasone Versus Bortezomib + Thalidomide + Dexamethasone: A Matching Adjusted Indirect Comparison
Shaji Kumar, N. Callander, Kehinde Adekola, L. Anderson, M. Baljevic, E. Campagnaro, J. Castillo, J. Chandler, C. Costello, Y. Efebera, M. Faiman, A. Garfall, K. Godby, J. Hillengass, L. Holmberg, M. Htut, C. Huff, Yubin Kang, M. Hultcrantz, Sarah Larson, M. Liedtke, T. Martin, J. Omel, K. Shain, D. Sborov, K. Stockerl-Goldstein, D. Weber, J. Keller, Rashmi Kumar (2009)NCCN clinical practice guidelines in oncology: multiple myeloma.
Journal of the National Comprehensive Cancer Network : JNCCN, 7 9
(2016)KYPROLIS ® ( carfilzomib ) for injection , for intravenous use : US prescribing information
M. Dimopoulos, A. Stewart, S. Rajkumar, T. Masszi, A. Oriol, R. Hájek, L. Rosiñol, D. Siegel, G. Mihaylov, V. Goranova-Marinova, P. Rajnics, A. Suvorov, R. Niesvizky, A. Jakubowiak, J. Miguel, H. Ludwig, N. Zojwalla, P. Moreau, A. Palumbo (2015)Effect of carfilzomib, lenalidomide, and dexamethasone (KRd) vs lenalidomide and dexamethasone (Rd) in patients with relapsed multiple myeloma (RMM) by line of therapy: Secondary analysis from an interim analysis of the phase III study ASPIRE (NCT01080391).
Journal of Clinical Oncology, 33
Guang Yang, Minjie Gao, Yiwen Zhang, Y. Kong, Lu Gao, Y. Tao, Ying Han, Huiqun Wu, Xiu-qin Meng, Hongwei Xu, F. Zhan, Xiaosong Wu, Jumei Shi (2015)Carfilzomib enhances natural killer cell-mediated lysis of myeloma linked with decreasing expression of HLA class I
M. Alsina, S. Trudel, R. Furman, P. Rosen, O. O’Connor, R. Comenzo, A. Wong, L. Kunkel, C. Molineaux, A. Goy (2012)A Phase I Single-Agent Study of Twice-Weekly Consecutive-Day Dosing of the Proteasome Inhibitor Carfilzomib in Patients with Relapsed or Refractory Multiple Myeloma or Lymphoma
Clinical Cancer Research, 18
T. Hideshima, P. Richardson, K. Anderson (2011)Mechanism of Action of Proteasome Inhibitors and Deacetylase Inhibitors and the Biological Basis of Synergy in Multiple Myeloma
Molecular Cancer Therapeutics, 10
S. Usmani, P. Rodríguez-Otero, M. Bhutani, M. Mateos, J. Miguel (2015)Defining and treating high-risk multiple myeloma
Carfilzomib (Kyprolis®) is a proteasome inhibitor that binds selectively and irreversibly to the 20S proteasome (the proteolytic core particle within the 26S proteasome), inducing growth arrest and apoptosis. This intravenous drug is approved in the EU and the USA as combination therapy with oral lenalidomide and intravenous or oral dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy. In the multinational, phase III ASPIRE study in this patient population, carfilzomib triple combination therapy significantly prolonged progression-free survival (PFS), reflecting a clinically relevant gain in PFS of 8.7 months, compared with lenalidomide plus dexamethasone. Improvements in overall response rate and patients’ global health status were also observed with carfilzomib triple combination therapy. A significant improvement in overall survival (OS) is yet to be demonstrated, with the prespecified stopping boundary not crossed at the time of the prespecified interim analysis, although OS data were not mature by the cut-off date. Carfilzomib triple combination therapy had a manageable tolerability profile. The incidences of the most frequently reported grade 3 or higher adverse events of special interest (with the exception of neutropenia, anaemia and thrombocytopenia) were low in both the carfilzomib triple combination therapy and lenalidomide plus dexamethasone groups. Although final OS data are awaited, current evidence suggests carfilzomib in combination with lenalidomide and dexamethasone is a welcome addition to the treatment options currently available for patients with relapsed multiple myeloma.
Targeted Oncology – Springer Journals
Published: Mar 14, 2016
Access the full text.
Sign up today, get DeepDyve free for 14 days.